Drug Innovation
Commentary
Price Controls Are Disastrous For Rents And Will Be For Drugs
President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president ...
Commentary
President Trump’s Big Government Instincts Threaten Drug Innovation And Availability
President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the ...
Commentary
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
Blog
What We’re Watching – Good Friday Edition
Tim Anaya – The Crossroads of Innovation and Affordability In the latest “Escape the Drug Pricing Maze” video, On the first step toward escaping the Drug Pricing Maze, Professor Salvare takes Pete Paystoomuch down the path of drug innovation, showing him why drug prices are initially more expensive – to ...
Drug Innovation
Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show
Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Commentary
Don’t Slash Medicare In Last – Minute Budget Agreement
The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans ...
Drug Innovation
Wayne Winegarden Biosimilar Study Featured in Fierce Healthcare
Report: Growing biosimilar market could save billions in health spending By Paige Minemyer Growing the biosimilar market could lead to significant healthcare cost savings, according to a new report, with the opportunity for billions in cost reductions. An analysis (PDF) from the Pacific Research Institute, a free market think tank, shows today ...
Drug Innovation
PRI’s biosimilars study featured in Politico’s Prescription Pulse newsletter
The Pacific Research Institute’s Center for Medical Economics and Innovation study on biosimilars was published in Politico’s Prescription Pulse newsletter.
Commentary
How socialist price controls will harm American patients
The Trump administration is planning to propose one of the biggest changes to Medicare in decades. The draft rule aims to reduce government spending by linking Medicare drug reimbursement rates to the rates in more than a dozen other Western countries that use price controls to hold down pharmaceutical spending. If implemented, ...
Business & Economics
Protecting The Medicines Of Tomorrow
Government solutions often come with a price. For the America Invents Act (AIA), this price was an unintended impediment to medical innovation. Proposed legislation known as the Hatch-Waxman Integrity Act can reduce these costs, if Congress takes advantage of the opportunity. The problem of patent trolls plaguing Silicon Valley was ...
Price Controls Are Disastrous For Rents And Will Be For Drugs
President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president ...
President Trump’s Big Government Instincts Threaten Drug Innovation And Availability
President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the ...
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
What We’re Watching – Good Friday Edition
Tim Anaya – The Crossroads of Innovation and Affordability In the latest “Escape the Drug Pricing Maze” video, On the first step toward escaping the Drug Pricing Maze, Professor Salvare takes Pete Paystoomuch down the path of drug innovation, showing him why drug prices are initially more expensive – to ...
Sally C. Pipes Discusses Changing Drug Regulations on the Lars Larson Show
Sally C. Pipes joins the Lars Larson Show on KXL to discuss how new regulations will change drug prices in Canada and discourage drug innovation.
Don’t Slash Medicare In Last – Minute Budget Agreement
The weather isn’t the only thing heating up in Washington. White House officials are feverishly negotiating with congressional leaders to raise the debt ceiling and reach a two-year budget deal that averts more than $126 billion in automatic spending cuts. Democrats want the deal to dramatically raise domestic spending levels. Republicans ...
Wayne Winegarden Biosimilar Study Featured in Fierce Healthcare
Report: Growing biosimilar market could save billions in health spending By Paige Minemyer Growing the biosimilar market could lead to significant healthcare cost savings, according to a new report, with the opportunity for billions in cost reductions. An analysis (PDF) from the Pacific Research Institute, a free market think tank, shows today ...
PRI’s biosimilars study featured in Politico’s Prescription Pulse newsletter
The Pacific Research Institute’s Center for Medical Economics and Innovation study on biosimilars was published in Politico’s Prescription Pulse newsletter.
How socialist price controls will harm American patients
The Trump administration is planning to propose one of the biggest changes to Medicare in decades. The draft rule aims to reduce government spending by linking Medicare drug reimbursement rates to the rates in more than a dozen other Western countries that use price controls to hold down pharmaceutical spending. If implemented, ...
Protecting The Medicines Of Tomorrow
Government solutions often come with a price. For the America Invents Act (AIA), this price was an unintended impediment to medical innovation. Proposed legislation known as the Hatch-Waxman Integrity Act can reduce these costs, if Congress takes advantage of the opportunity. The problem of patent trolls plaguing Silicon Valley was ...
